APC anti-mouse CD206 (MMR) Antibody

Pricing & Availability
Clone
C068C2 (See other available formats)
Regulatory Status
RUO
Other Names
MMR (macrophage mannose receptor), MR (mannose receptor), MRC1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
C068C2_APC_1_082911
Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) PE, and then intracellularly stained with CD206 (clone C068C2) APC (top) or rat IgG2a, κ APC isotype control (bottom).
  • C068C2_APC_1_082911
    Thioglycollate-elicited BALB/c peritoneal macrophages were surface stained with CD107b (Mac-3) PE, and then intracellularly stained with CD206 (clone C068C2) APC (top) or rat IgG2a, κ APC isotype control (bottom).
  • C068C2_APC_2_082911
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
141707 25 µg £90
Check Availability


Need larger quantities of this item?
Request Bulk Quote
141708 100 µg £203
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD206, also known as mannose receptor (MR), is a 175 kD type I membrane protein. It is a pattern recognition receptor (PRR) belonging to the C-type lectin superfamily. MR is expressed on macrophages, dendritic cells, Langerhans cells, and hepatic or lymphatic endothelial cells. MR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine through its C-type lectin-like carbohydrate recognition domains, sulfated carbohydrate antigens through its cysteine-rich domain, and collagens through its fibronectin type II domain. MR mediates endocytosis and phagocytosis as well as activation of macrophages and antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity. Recently, MR on lymphatic endothelial cells was found to be involved in leukocyte trafficking and a contributor to the metastatic behavior of cancer cells. It suggests that MR may be a potential target in controlling inflammation and cancer metastasis by targeting the lymphatic vasculature.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Recombinant mouse CD206 (MMR)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
FC - Verified

Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone C068C2 recognizes a region similar to clone MR5D3, based on the ability of the clones to block each other. Additional reported applications (for the relevant formats) include: spatial biology (IBEX)4,5.

Application References

(PubMed link indicates BioLegend citation)
  1. Keller J, et al. 2012. Biochem Biophys Res Commun. 417:217. PubMed
  2. Ito H, et al. 2012. J Am Soc Nephrol. 23:1797. PubMed
  3. Yang X, et al. 2015. PNAS. 112:2900. PubMed
  4. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Liu J, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.139. PubMed
  2. Wang C, et al. 2018. J Pharmacol Exp Ther. 365:72. PubMed
  3. Jiang Z, et al. 2021. J Clin Invest. 131: . PubMed
  4. Kiepura A, et al. 2021. Int J Mol Sci. 22:. PubMed
  5. Yokozeki Y, et al. 2021. Biomed Res Int. 2021:7988320. PubMed
  6. Liu C, et al. 2022. Regen Ther. 21:192. PubMed
  7. Pathak JL, et al. 2021. Front Cell Dev Biol. 628139:9. PubMed
  8. Jeong J, et al. 2017. Sci Rep. 7:39848. PubMed
  9. Poh AR, et al. 2017. Cancer Cell. 31:563. PubMed
  10. Liu C, et al. 2019. J Transl Med. 17:300. PubMed
  11. Zhang X, et al. 2017. J Cell Mol Med. 10.1111/jcmm.13329. PubMed
  12. Hong M, et al. 2021. Int J Mol Sci. 22:. PubMed
  13. El-Hindi K, et al. 2022. Int J Mol Sci. 23:. PubMed
  14. He J, et al. 2022. Front Immunol. 12:760138. PubMed
  15. Giordano C, et al. 2014. Hum Mol Genet. . PubMed
  16. Mylonas K, et al. 2015. Immunobiology. 220: 924-933. PubMed
  17. Cardona S, et al. 2015. ASN Neuro. 7: 1759091415608204. PubMed
  18. Tahiri H, et al. 2016. Sci Rep. 6:37391. PubMed
  19. Kurelac I, et al. 2019. Nat Commun. 10:903. PubMed
  20. Chang CF, et al. 2017. Neurobiol Dis. 103:54. PubMed
  21. Pilch Z, et al. 2018. Cancer Immunol Res. 6:930. PubMed
  22. Zhang J, et al. 2021. Front Cardiovasc Med. 8:737652. PubMed
  23. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  24. Liang S, et al. 2022. Acta Pharm Sin B. 12:2494. PubMed
  25. Adachi Y, et al. 2022. Nat Commun. 13:5117. PubMed
  26. Yuan Q, et al. 2021. Cell Reports. 34(5):108724. PubMed
  27. Young JA, et al. 2020. Journal of Neuroendocrinology. e12854.. PubMed
  28. Shang W, et al. 2019. J Diabetes Res. 2019:5641271. PubMed
  29. Nawaz A, et al. 2022. Nat Commun. 13:7058. PubMed
  30. Zhang L, et al. 2022. Acta Pharm Sin B. 12:3427. PubMed
  31. Chen X, et al. 2021. Cell Death Differ. 28:1237. PubMed
  32. Trott DW, et al. 2021. Geroscience. 43:1331. PubMed
  33. Wada N, et al. 2020. Mol Metab. 37:100988. PubMed
  34. Zhu B, et al. 2021. Immunity. 54(6):1200-1218.e9. PubMed
  35. Motoyama S, et al. 2020. Cells. :9. PubMed
  36. Li S, et al. 2021. Ann Transl Med. 9:1644. PubMed
  37. Chen F, et al. 2022. Evid Based Complement Alternat Med. 2022:1240242. PubMed
  38. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  39. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  40. Li Q, et al. 2021. Brain Behav Immun. 94:437. PubMed
  41. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  42. Qiu J, et al. 2016. Sci Rep. 6:39407. PubMed
  43. Lasky C, et al. 2015. Infect Immun . 83: 2627 - 2635. PubMed
  44. van Dierendonck XAMH, et al. 2020. Cell Reports. 30(6):1811-1822. PubMed
  45. Mariani SA, et al. 2019. Immunity. 50:1439. PubMed
  46. Yan J, et al. 2018. Nat Commun. 9:33. PubMed
  47. Kan C, et al. 2022. Bone Res. 10:62. PubMed
  48. Liao Y, et al. 2020. Mol Ther. 28:855. PubMed
  49. Hu M, et al. 2022. Can Respir J. 2022:5802938. PubMed
  50. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  51. Xie Z, et al. 2021. Open Life Sci. 16:653. PubMed
  52. Wu L, et al. 2022. Front Cell Dev Biol. 9:684842. PubMed
  53. Chen X, et al. 2022. J Appl Oral Sci. 30:e20220316. PubMed
  54. Taguchi K, et al. 2015. J Urol. . PubMed
  55. Calvo B, et al. 2020. IBRO Rep. 8:36. PubMed
  56. Jin RM, et al. 2017. J Immunol. 198:352. PubMed
  57. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  58. Xiao Y, et al. 2022. Clin Transl Med. 12:e1071. PubMed
  59. Feng T, et al. 2022. Nat Commun. 13:5208. PubMed
  60. Kornstädt L, et al. 2021. Front Immunol. 11:607048. PubMed
  61. Chen L, et al. 2021. Cell Death Differ. 28:1880. PubMed
  62. Taguchi K, et al. 2014. J Am Soc Nephrol. 25:1680. PubMed
  63. Rios-Doria J, et al. 2021. Front Oncol. 10:598477. PubMed
  64. Ayala TS, et al. 2019. Sci Rep. 9:11447. PubMed
  65. Mallampalli RK, et al. 2021. Front Immunol. 12:735576. PubMed
  66. Xu Z, et al. 2020. Cancer Immunol Res. 1354:8. PubMed
  67. Xue N, et al. 2017. Sci Rep. 7:39011. PubMed
  68. Lee JY, et al. 2020. Nat Commun. 11:2358. PubMed
  69. Yoon J, et al. 2020. Front Cell Dev Biol. 0.520138889. PubMed
  70. Kumar MP, et al. 2018. Cell Rep. 25:1458. PubMed
  71. Wang Q, et al. 2018. Nat Commun. 9:559. PubMed
  72. Xu M, et al. 2022. Genes Dis. 9:429. PubMed
  73. Ganesan R, et al. 2020. FASEB J. 34:15888. PubMed
  74. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  75. Moya-Pérez A, et al. 2015. PLoS One. 10: 0126976. PubMed
  76. De Simone G, et al. 2021. Immunity. :. PubMed
  77. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  78. Sasaki T, et al. 2020. Cell Reports. 28(1):202-217.e7.. PubMed
  79. Zhou X, et al. 2022. Front Pharmacol. 13:872188. PubMed
  80. Blriot C, et al. 2021. Immunity. :. PubMed
  81. Koikawa K, et al. 2021. Cell. 184(18):4753-4771.e27. PubMed
  82. Yamakawa D, et al. 2021. Cell Reports. 34(10):108817. PubMed
  83. Luo J et al. 2018. Immunity. 49(1):107-119 . PubMed
  84. Sun S, et al. 2021. Front Immunol. 12:777665. PubMed
  85. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  86. Zhang S, et al. 2021. J Inflamm Res. 14:4915. PubMed
  87. Sun M, et al. 2021. J Immunother Cancer. 9:. PubMed
  88. Fan Q, et al. 2021. Bioact Mater. 6:4014. PubMed
  89. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  90. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  91. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  92. Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed
  93. Fujimoto N, et al. 2020. PLoS Biol. 18:e3000704. PubMed
  94. Remmerie A, et al. 2020. Immunity. 53:641. PubMed
  95. Quenum Zangbede FO, et al. 2018. J Neurosci. 38:6737. PubMed
  96. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  97. Trott DW, et al. 2021. J Physiol. 599:3973. PubMed
  98. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  99. Dong R, et al. 2021. Frontiers in Immunology. 12:620238. PubMed
  100. Zhang Y, et al. 2020. Mol Med Rep. 22:534. PubMed
  101. Kiyohara H, et al. 2018. Cell Mol Gastroenterol Hepatol. 7:135. PubMed
  102. Guo D, et al. 2022. Bone Res. 10:45. PubMed
  103. Yuan M, et al. 2022. Oxid Med Cell Longev. 2022:5479491. PubMed
  104. Li ZL, et al. 2021. Mol Ther Nucleic Acids. 25:502. PubMed
  105. He H, et al. 2012. Blood. 120:3152. PubMed
  106. Dai K, et al. 2015. J Leukoc Biol. 98: 1071 - 1080. PubMed
  107. Settelmeier S, et al. 2020. PLoS One. 15:e0233261. PubMed
  108. Gao Z, et al. 2022. J Inflamm Res. 15:3337. PubMed
  109. Tomimatsu M, et al. 2022. Sci Rep. 12:16656. PubMed
  110. Li K, et al. 2020. J Cell Mol Med. 24:13115. PubMed
  111. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  112. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  113. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  114. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  115. Nam J, et al. 2021. Adv Ther (Weinh). 4:. PubMed
  116. Canedo T, et al. 2021. Neuropsychopharmacology. 46:2358. PubMed
  117. Zhang W, et al. 2021. Front Immunol. 12:768435. PubMed
  118. Roux C, et al. 2021. Antioxidants (Basel). 10:. PubMed
  119. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  120. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  121. Lee SH, et al. 2018. J Exp Med. 215:357. PubMed
  122. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  123. Tang PC, et al. 2022. Adv Sci (Weinh). 9:e2101235. PubMed
  124. Cui Y, et al. 2022. Front Oncol. 12:732860. PubMed
  125. Siolas D, et al. 2021. Cell Reports. 36(8):109578. PubMed
  126. Canan C, et al. 2014. J Leukoc Biol. 96:473. PubMed
  127. Lee C, et al. 2020. Front Immunol. 11:77. PubMed
  128. Gundra UM, et al. 2017. Nat Immunol. 1.195833333. PubMed
  129. Catrysse L, et al. 2021. Cell Rep. 36:109748. PubMed
  130. Zhu Y, et al. 2021. Int J Oral Sci. 13:25. PubMed
  131. Filtjens J, et al. 2021. Nat Commun. 12:2936. PubMed
  132. Baardman J et al. 2018. Cell reports. 25(8):2044-2052 . PubMed
  133. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
  134. Durga Devi T, et al. 2017. Am J Pathol. 187:2659. PubMed
  135. Kurelac I, et al. 2019. J Clin Med. 1.85. PubMed
  136. Crowe J, et al. 2020. PLoS Pathog. 16:e1008391. PubMed
  137. Song HY, et al. 2021. Mol Ther. S1525-0016:00472-X. PubMed
  138. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  139. Liu Y, et al. 2019. Am J Physiol Cell Physiol. 317:C762. PubMed
  140. Syed I et al. 2018. Cell metabolism. 27(2):419-427 . PubMed
  141. Nasti A, et al. 2017. Eur J Immunol. 47:2163. PubMed
  142. Chithanathan K, et al. 2022. Biology (Basel). 11:. PubMed
  143. Ding T, et al. 2021. J Nanobiotechnology. 19:247. PubMed
  144. Andreata F, et al. 2021. STAR Protoc. 2:100831. PubMed
RRID
AB_10896057 (BioLegend Cat. No. 141707)
AB_10900231 (BioLegend Cat. No. 141708)

Antigen Details

Structure
Type I transmembrane protein, 175 kD, C-type lectin superfamily
Distribution

Macrophages, dendritic cells, Langerhans cells, liver endothelial cells

Function
Pathogen recognition, endocytosis and phagocytosis, antigen presentation
Ligand/Receptor
Antigen containing mannose, fucose, or an N-acetyl glucosamine
Cell Type
Dendritic cells, Endothelial cells, Langerhans cells, Macrophages
Biology Area
Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family
CD Molecules
Antigen References

1. Wileman TE, et al. 1986. P. Natl. Acad. Sci. USA 83:2501.
2. Apostolopoulos V, et al. 2001. Curr. Mol. Med. 1:469.
3. Burgdorf S, et al. 2006. J. Immunol. 176:6770.
4. McKenzie EJ, et al. 2007. J. Immunol. 178:4975.

Gene ID
17533 View all products for this Gene ID
UniProt
View information about CD206 on UniProt.org

Related FAQs

Why is mouse CD206 stained intracellularly and not via surface staining?

Typically, mouse CD206 surface level is relatively low under normal conditions and so intracellular staining protocol is required to get better signal.

Go To Top Version: 3    Revision Date: 04/04/2016

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Biotin anti-mouse CD206 (MMR)

  • Purified anti-mouse CD206 (MMR)

  • FITC anti-mouse CD206 (MMR)

  • PE anti-mouse CD206 (MMR)

  • APC anti-mouse CD206 (MMR)

  • Alexa Fluor® 488 anti-mouse CD206 (MMR)

  • Alexa Fluor® 647 anti-mouse CD206 (MMR)

  • PerCP/Cyanine5.5 anti-mouse CD206 (MMR)

  • PE/Cyanine7 anti-mouse CD206 (MMR)

  • Brilliant Violet 421™ anti-mouse CD206 (MMR)

  • Brilliant Violet 605™ anti-mouse CD206 (MMR)

  • Brilliant Violet 650™ anti-mouse CD206 (MMR)

  • Alexa Fluor® 594 anti-mouse CD206 (MMR)

  • Brilliant Violet 711™ anti-mouse CD206 (MMR)

  • Brilliant Violet 785™ anti-mouse CD206 (MMR)

  • PE/Dazzle™ 594 anti-mouse CD206 (MMR)

  • Alexa Fluor® 700 anti-mouse CD206 (MMR)

  • Spark YG™ 570 anti-mouse CD206 (MMR)

  • PE/Cyanine5 anti-mouse CD206 (MMR)

  • PE/Fire™ 700 anti-mouse CD206 (MMR)

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account